Deracoxib-d3

Modify Date: 2024-04-11 18:01:40

Deracoxib-d3 structure	Common Name	Deracoxib-d3
	CAS Number	2012598-48-8	Molecular Weight	400.39
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₇H₁₁D₃F₃N₃O₃S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Deracoxib-d3

Deracoxib-d3 is the deuterium labeled Deracoxib. Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).

Name	Deracoxib-d3

Description	Deracoxib-d3 is the deuterium labeled Deracoxib. Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> COX
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66(11): p. 1961-7. [3]. Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740. [4]. Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41(3): p. 336-44. [5]. McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239(8): p. 1084-9.

Molecular Formula	C₁₇H₁₁D₃F₃N₃O₃S
Molecular Weight	400.39